DMAC · DiaMedica Therapeutics Inc.
$6.52
+0.00 (+0.00%)
At close · Aug 21
Market Cap
$351.60M
Shares
53.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.52
Open$6.58
Day$6.50–6.73
52W close$5.30–9.39
Avg vol 30d159K
Short int5.2M · 9.6% float · 27.4d
Short vol49%
Last earningsAug 11, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−4%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
30%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−16%
trailing
YTD return
−18%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.65% of float · ▲ +1.8% MoM · 27.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
87 holders — mid 3-yr range
Squeeze score
79
high risk · 0–100
Fundamentals
Free cash flow
$-29.1M
Balance sheet
$15.6M
net cash
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
30%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.65% of float · ▲ +1.8% MoM · 27.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
87 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $7 · 30%
Range high $9
vs 200-day avg -9%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Activated sites | 70 | Q2 2026 | — |
| Mean reduction in diastolic blood pressure (DBP) in combined final, highest-dose cohorts (cohort | 17 | Part 1a topline results | — |
| Mean reduction in systolic blood pressure (SBP) in combined final, highest-dose cohorts (cohort | 29.1 | Part 1a topline results | — |
| Phase 2/3 ReMEDy2 trial enrollment (percent of 200 participants required for interim analysis) | 85% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAC
this stock
DiaMedica Therapeutics Inc.
|
$351.60M | -18.1% | — | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +20.9% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAC | -2.4% | -3.2% | -16.2% | +2.8% | -18.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -1.0% | -6.8% | -27.8% | +0.3% | -30.4% |